Canada approves indication expansion for Novo Nordisk hemophilia drug

Novo Nordisk’s hemophilia drug Rebinyn can now be prescribed to children and young people with hemophilia B in the North American country.

Photo: Novo Nordisk / PR

Five years after it was first approved in the country, Health Canada has expanded the indication for Novo Nordisk’s hemophilia B treatment Rebinyn to include children and young people.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs